JP6041242B2 - トリプトファンを含有するペプチド - Google Patents
トリプトファンを含有するペプチド Download PDFInfo
- Publication number
- JP6041242B2 JP6041242B2 JP2013532122A JP2013532122A JP6041242B2 JP 6041242 B2 JP6041242 B2 JP 6041242B2 JP 2013532122 A JP2013532122 A JP 2013532122A JP 2013532122 A JP2013532122 A JP 2013532122A JP 6041242 B2 JP6041242 B2 JP 6041242B2
- Authority
- JP
- Japan
- Prior art keywords
- tryptophan
- stress
- hydrolyzate
- trp
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title claims description 72
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title claims description 69
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 title description 15
- 239000000203 mixture Substances 0.000 claims description 36
- 230000035882 stress Effects 0.000 claims description 28
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 27
- 108010014251 Muramidase Proteins 0.000 claims description 16
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 16
- 235000010335 lysozyme Nutrition 0.000 claims description 16
- 229960000274 lysozyme Drugs 0.000 claims description 16
- 239000004325 lysozyme Substances 0.000 claims description 16
- 230000037406 food intake Effects 0.000 claims description 14
- 235000019789 appetite Nutrition 0.000 claims description 13
- 230000036528 appetite Effects 0.000 claims description 13
- 235000015872 dietary supplement Nutrition 0.000 claims description 12
- 235000005686 eating Nutrition 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 9
- 235000012631 food intake Nutrition 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- 230000037328 acute stress Effects 0.000 claims description 7
- 230000037326 chronic stress Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108090000787 Subtilisin Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 description 66
- 229940024606 amino acid Drugs 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 102100033468 Lysozyme C Human genes 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000047 product Substances 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 102000002322 Egg Proteins Human genes 0.000 description 7
- 108010000912 Egg Proteins Proteins 0.000 description 7
- 239000003531 protein hydrolysate Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000014103 egg white Nutrition 0.000 description 6
- 210000000969 egg white Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 102000004407 Lactalbumin Human genes 0.000 description 5
- 108090000942 Lactalbumin Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 235000011888 snacks Nutrition 0.000 description 5
- 108010009736 Protein Hydrolysates Proteins 0.000 description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000021241 α-lactalbumin Nutrition 0.000 description 4
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000021056 liquid food Nutrition 0.000 description 3
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000012182 cereal bars Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 235000020803 food preference Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 235000000053 special nutrition Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000021557 concentrated beverage Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020931 dietary conditions Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- UZCGKGPEKUCDTF-UHFFFAOYSA-N fluazinam Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=C(Cl)C([N+]([O-])=O)=C1NC1=NC=C(C(F)(F)F)C=C1Cl UZCGKGPEKUCDTF-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000015219 food category Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000020772 multivitamin supplement Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000012434 pretzels Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fodder In General (AREA)
Description
本発明は、ストレス曝露時および後の間食の低減に関する。
ストレスは食品の嗜好および摂取に影響を及ぼすことが多い。ストレスは食欲不振の原因となり得るが、多くの研究から一貫して、軽度ないし中程度の急性ストレスが甘い高脂肪食品の嗜好および摂取を高め、かつストレスで誘発される情動摂食が、セロトニン(5−HTergic)神経伝達または機能の減少に起因し得ることが明らかになっている。
本発明は、経口摂取用のトリプトファン含有ペプチドまたはトリプトファン含有加水分解産物に関する。驚くべきことに、トリプトファン含有ペプチドまたはトリプトファン含有加水分解産物を経口摂取すると、数時間の食品摂取の低減によって証明される、摂食または食欲の減少が生じることが判明した。本発明の実施形態に従って、トリプトファン含有ペプチドまたはトリプトファン含有加水分解産物が、経口摂取のために、好ましくは摂食または食欲を減少させるために使用される。
ストレスは、ヒトの摂食行動にネガティブな影響をもたらすと考えられる。ストレスによって、食物摂取が変化し、その結果、間食または過食となり得る。少なくとも2種類のストレスが重要な役割を担っていると思われる。慢性(生活上の)ストレスならびに急性ストレスは、甘みおよび脂肪に対する高い嗜好に関連し得る。その結果は、体重が増加することが多く、最終的には肥満症の発症を引き起こし得る。
[材料]
商品名「Protex 6L」のサブチリシンが、Genencor(Leiden,The Netherlands)から入手された。リゾチームは、DSM Food Specialities(Delft,The Netherlands)からDelvozyme L(乾物22%)として入手された。
Waters(Milford MA,USA)のAmino Acid Analysis Systemの使用説明書で指定されるPicoTag法に従って、アミノ酸分析を行った。その目的のために、試料を乾燥させ、フェニルイソチオシアネートを使用して直接、誘導体化した。記載のようにHPLC法を用いて、存在する誘導体化アミノ酸を定量化した。通常の酸加水分解中にTrpおよびCysが破壊されるため、特別な方法を用いて、これら2種類のアミノ酸を定量化した。加水分解中のCysの分解を防ぐために、過酸化水素を使用して、このアミノ酸を最初にシステイン酸に酸化し、次いで定量化する。トリプトファンの分析は、わずかに変更されたWaters手順に基づく。この手順では、ペプチド溶液のアリコートを真空下にて乾燥させ、次いで窒素下にて150℃で1時間、0.2%トリプタミンを含有する4Mメタンスルホン酸中で加水分解する。Alltech Altima C18カラムおよび蛍光検出を備えたHPLCを使用して、反応生成物を直接、定量化する。
種々のプロトン性混合物と共にインキュベートする間に得られる加水分解度(DH)を、迅速OPA試験を用いてモニターした(Nielsen,P.M.;Petersen,D.;Dambmann,C.Improved method for determining food protein degree of hydrolysis.Journal of Food Science 2001,66,642−646)。
[実施例1]
[トリプトファン豊富な加水分解産物を生成するための、Protexを使用したリゾチームの加水分解]
NaOHを使用して、純粋リゾチーム10%(w/w)を含有する溶液をpH8.2に調整し、52℃に加熱した。存在するタンパク質1g当たりProtex25マイクロリットルを添加して、加水分解を開始した。連続攪拌し、pHを8.2に維持しながら、加水分解を5.5時間続けて、目に見える沈殿物なく、ほぼ透明な溶液が得られた。Protex活性を不活化するための加熱工程後、DH分析から試料を採取した。溶液のDHはほぼ30%に変化した。熱処理された溶液を10kDaフィルター上で限外濾過し、完全に透明な液体が得られた(トリプトファン豊富な加水分解産物またはトリプトファン豊富な加水分解タンパク質)。
[トリプトファン豊富な加水分解産物を使用した、ストレスにより誘発される間食の減少]
この研究は、二重盲検プラセボ対照交差デザインに従って行った。2つの実験セッション中、参加者42名それぞれが研究室を訪問し、急性ストレス曝露前および後、ならびにトリプトファン豊富な加水分解タンパク質(THP、実施例1参照)またはプラシーボタンパク質(PLC)のいずれかの摂取後にモニターした。食事条件の指示は、少なくとも1週間の休薬期間と共に2日の試験日にわたって釣り合わせた。
両方の実験セッション中、トリプトファン豊富な卵タンパク質加水分解産物、THP(DSM Delft;The Netherlands)またはプラシーボのカゼインタンパク質加水分解産物(PLC,DSM Delft;The Netherlands)のいずれかを含有する飲料を摂取した。製品の重要な特徴を表1に示す。
間食行動を測定するために、ストレス曝露前(準備前)およびストレス曝露後に、予め計量された量のスナック食品(ミニキャンディーバー、プレッツェルおよびナッツ)を置いた食品トレイを参加者に差し出した。公開演説(インタビュー)課題の準備後およびその完了後の各時点で、食品容器を計量して、食物摂取の総量を決定した。
分析から、主な治療効果(P=0.037)が明らかとなり、PLC(55g±50g)と比較してTHP(34g±27g)後に総量で21gの食物摂取の減少が示され(図1参照)、リゾチーム加水分解産物およびトリプトファン含有ペプチドを含む他のトリプトファン含有加水分解産物によって、ストレス時の間食が低減されることが実証されている。
Claims (6)
- トリプトファン含有ペプチドを含み、かつ0.21以上のTrp/LNAA比を有し、前記トリプトファン含有ペプチドがトリプトファン含有加水分解産物の形で存在する、ストレス時またはストレス後の摂食または食欲を低減するための組成物であって、前記トリプトファン含有加水分解産物は、リゾチームをサブチリシンにより加水分解度が30%に達するまで加水分解して得られ、10kDa未満の分子量を有する加水分解産物である、組成物。
- 0.21〜1.8のTrp/LNAA比を有する、請求項1に記載の組成物。
- 前記ストレスが慢性ストレスまたは急性ストレスである、請求項1または2に記載の組成物。
- ストレス時またはストレス後の摂食または食欲の減少を得るための薬剤、食品もしくは飲料、食事性サプリメント、栄養補助剤、または、飼料もしくはペットフードの製造における、請求項1に記載の組成物の使用。
- 前記組成物が0.21〜1.8のTrp/LNAA比を有する、請求項4に記載の組成物の使用。
- 前記ストレスが慢性ストレスまたは急性ストレスである、請求項4または5に記載の組成物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10186571 | 2010-10-05 | ||
EP10186571.5 | 2010-10-05 | ||
PCT/EP2011/066801 WO2012045617A1 (en) | 2010-10-05 | 2011-09-28 | Peptides containing tryptophan |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013541540A JP2013541540A (ja) | 2013-11-14 |
JP6041242B2 true JP6041242B2 (ja) | 2016-12-07 |
Family
ID=44719928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013532122A Active JP6041242B2 (ja) | 2010-10-05 | 2011-09-28 | トリプトファンを含有するペプチド |
Country Status (9)
Country | Link |
---|---|
US (1) | US9629890B2 (ja) |
EP (1) | EP2624850B1 (ja) |
JP (1) | JP6041242B2 (ja) |
KR (1) | KR101957531B1 (ja) |
CN (1) | CN103153326B (ja) |
BR (1) | BR112013008096A2 (ja) |
ES (1) | ES2545187T3 (ja) |
PL (1) | PL2624850T3 (ja) |
WO (1) | WO2012045617A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110086803A1 (en) | 2006-11-02 | 2011-04-14 | Andre Leonardus De Roos | Peptides containing tryptophan |
US9629890B2 (en) * | 2010-10-05 | 2017-04-25 | Dsm Ip Assets B.V. | Peptides containing tryptophan |
EP2701716B1 (en) | 2011-04-28 | 2017-11-01 | DSM IP Assets B.V. | Protein hydrolysates as agents for overcoming addiction |
TR201809789T4 (tr) * | 2012-11-02 | 2018-07-23 | Dsm Ip Assets Bv | Triptofan bakımından zengin protein hidrolisatlarının kullanımı. |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02279700A (ja) | 1989-04-19 | 1990-11-15 | Asahi Chem Ind Co Ltd | 高トリプトファン含有ペプチド |
DE4130284A1 (de) | 1991-09-12 | 1993-03-18 | Willi Prof Dr Med Habil Heine | Verfahren zur herstellung biologisch hochwertiger nahrungseiweisse |
AU3666497A (en) * | 1996-07-17 | 1998-02-09 | Nutracorp Scientific, Inc. | Appetite suppression |
US6579899B1 (en) * | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
WO2002046210A1 (en) | 2000-12-06 | 2002-06-13 | Campina Melkunie B.V. | Method for preparing tryptophan rich peptides |
DE60333868D1 (de) | 2003-02-07 | 2010-09-30 | Campina Bv | Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit |
US7064104B2 (en) * | 2003-06-13 | 2006-06-20 | The Procter & Gamble Company | Methods of managing the symptoms of premenstrual syndrome |
US20050089546A1 (en) * | 2003-09-16 | 2005-04-28 | Dick Wurtman | Compositions and methods comprising complex carbohydrate and alpha-lactalbumin |
CN101535494B (zh) * | 2006-11-02 | 2014-04-09 | 帝斯曼知识产权资产管理有限公司 | 含有色氨酸的肽 |
US20110086803A1 (en) * | 2006-11-02 | 2011-04-14 | Andre Leonardus De Roos | Peptides containing tryptophan |
WO2009133055A1 (en) | 2008-04-29 | 2009-11-05 | Dsm Ip Assets B.V. | Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan |
PL2282641T3 (pl) | 2008-04-29 | 2013-01-31 | Dsm Ip Assets Bv | Kompozycja zawierająca węglowodany i peptydy, które zawierają tryptofan |
US9629890B2 (en) * | 2010-10-05 | 2017-04-25 | Dsm Ip Assets B.V. | Peptides containing tryptophan |
-
2011
- 2011-09-28 US US13/877,561 patent/US9629890B2/en active Active
- 2011-09-28 KR KR1020137011360A patent/KR101957531B1/ko active IP Right Grant
- 2011-09-28 EP EP11761592.2A patent/EP2624850B1/en active Active
- 2011-09-28 WO PCT/EP2011/066801 patent/WO2012045617A1/en active Application Filing
- 2011-09-28 PL PL11761592T patent/PL2624850T3/pl unknown
- 2011-09-28 CN CN201180048202.8A patent/CN103153326B/zh active Active
- 2011-09-28 ES ES11761592.2T patent/ES2545187T3/es active Active
- 2011-09-28 BR BR112013008096A patent/BR112013008096A2/pt not_active Application Discontinuation
- 2011-09-28 JP JP2013532122A patent/JP6041242B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013541540A (ja) | 2013-11-14 |
EP2624850B1 (en) | 2015-07-08 |
ES2545187T3 (es) | 2015-09-09 |
KR20130139972A (ko) | 2013-12-23 |
US9629890B2 (en) | 2017-04-25 |
CN103153326B (zh) | 2015-08-19 |
BR112013008096A2 (pt) | 2016-08-09 |
EP2624850A1 (en) | 2013-08-14 |
WO2012045617A1 (en) | 2012-04-12 |
US20130296232A1 (en) | 2013-11-07 |
PL2624850T3 (pl) | 2015-11-30 |
CN103153326A (zh) | 2013-06-12 |
KR101957531B1 (ko) | 2019-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5626807B2 (ja) | ペプチド結合トリプトファンとポリペプチド結合トリプトファンの混合物 | |
US9993515B2 (en) | Methods of treatment using water-soluble tryptophan-containing peptides obtained by the hydrolysis of hens eggs lysozyme | |
WO2011108692A1 (ja) | 筋肉萎縮防止剤 | |
JP6041242B2 (ja) | トリプトファンを含有するペプチド | |
JP7358239B2 (ja) | エネルギー消費促進用組成物 | |
CN101535494A (zh) | 含有色氨酸的肽 | |
JP5695326B2 (ja) | タンパク質合成促進剤 | |
AU2010307691B2 (en) | Fat accumulation suppressor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160428 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160916 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160926 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161011 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161028 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6041242 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |